# Cipla: how the business works

> For learning only. Cityfort is not a SEBI-registered adviser and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

Cipla Limited · NSE: CIPLA · BSE: 500087 · Sector: Healthcare

Updated for Q2 FY27 · checked 11 Nov 2026

This is the plain-text version of https://cityfort.in/stocks/cipla. Source ids in [brackets] refer to the list at the end. Credit: "Cityfort, Cipla: how the business works", with the page URL.

## In short

Buyers in India, the US, Africa and other markets pay Cipla for its medicines; materials, staff and running costs take most of the money, and ₹13.4 of every ₹100 that came in was left as profit in FY26.

- In FY26 customers in India gave 45.0% of Cipla's revenue, the US 24.4%, Africa 15.2% and the rest of the world 15.4%.
- Of every ₹100 that came in during FY26, ₹32.9 went on materials, ₹25.4 on other running costs and ₹18.5 on staff.

## Key facts

**What does Cipla do?**

Cipla Ltd is a Mumbai-based drug maker, incorporated in 1935, that makes and sells medicines in India, the US, Africa and other markets. Cipla's FY26 revenue from operations was ₹28,163 crore, and it reported 48 manufacturing sites in its FY26 annual report. [S1, S48]

**How does Cipla make money?**

Cipla sells branded medicines that doctors prescribe in India, generic (off-patent) medicines in the US, Africa and other countries, and drug ingredients to other companies. In FY26 Cipla's India business sold ₹12,680 crore, North America ₹6,871 crore, Africa ₹4,287 crore and emerging markets and Europe ₹3,576 crore. [S16, S1]

**Who are Cipla's customers?**

In FY26 Cipla's revenue came 45.0% from customers in India, 24.4% from the US, 15.2% from Africa and 15.4% from the rest of the world. No single customer gave Cipla 10% or more of its revenue in FY26 or FY25. [S1]

**How big is Cipla?**

Cipla's FY26 revenue from operations was ₹28,163 crore and its profit for shareholders was ₹3,879 crore. Cipla reported more than 31,000 permanent employees and workers across 18 countries in its FY26 annual report. [S1, S15]

**Who owns Cipla?**

On 30 Sep 2026 Cipla's promoter group, the Hamied family with its trusts and companies, held 29.21% of the shares. Indian institutions held 34.94% (mutual funds 20.78%), foreign institutions 20.25% and other shareholders 15.60%. No promoter shares were pledged. [S46]

**Why did Cipla's profit fall in FY26?**

Cipla's FY26 profit for shareholders fell 26.4% to ₹3,879 crore while revenue rose 2.2%. Cipla's North America revenue fell 13% to ₹6,871 crore after billing of generic Revlimid (lenalidomide) ended and supply of lanreotide, made by a partner, was paused in Jan 2026. [S1, S16, S21, S78]

**How did Cipla do in Q2 FY27?**

In Q2 FY27 (Jul–Sep 2026) Cipla's revenue fell 2.4% to ₹7,404 crore and its profit for shareholders fell 35.1% to ₹878 crore. Cipla's India sales rose 12% to ₹3,516 crore, while North America sales fell 19% to ₹1,643 crore. [S6, S8]

**How much debt does Cipla have?**

On 30 Sep 2026 Cipla had borrowings of ₹267 crore and cash and liquid investments of ₹8,238 crore, plus ₹432 crore of lease liabilities. CARE Ratings rated Cipla's bank facilities CARE AAA (Stable) on 26 Aug 2025. [S6, S7, S47]

**What dividend does Cipla pay?**

Cipla's dividend for FY26 was ₹13 per share, 27.1% of its FY26 basic earnings per share of ₹48.03 (Cityfort calculation from the FY26 annual report). For FY25 Cipla paid ₹16, including a ₹3 special dividend for its 90th year. [S1, S2]

**Who runs Cipla?**

Achin Gupta has been Cipla's Managing Director and Global CEO since 1 Apr 2026, after Umang Vohra completed his term. Dr Y K Hamied, of the promoter family, is Cipla's Chairman, and Ashish Adukia is its Global CFO. [S1, S81]

## What does Cipla sell?

Cipla makes medicines. Most are generics: versions of drugs whose patents have expired. In India it sells them under its own brand names, which doctors prescribe. It is known for medicines for breathing (respiratory) conditions, including inhalers.

- **Medicines in India (One India):** Prescription brands, lower-priced trade generics sold through about 1.5 lakh retailers, and consumer health products: ₹12,680 crore of sales in FY26, up 9%. CARE's Aug 2025 report put Cipla's share of India's respiratory medicine market at 25.3%. [S16, S1, S47]
- **Generic medicines in North America:** Off-patent medicines, many of them inhalers, sold mainly in the US: ₹6,871 crore (US$780 million) in FY26, down 13%. Cipla's generic albuterol inhaler had 22% of the US albuterol inhaler market (IQVIA, week to 25 Sep 2026). [S16, S8]
- **Medicines in Africa (One Africa):** Branded and generic medicines in South Africa and other African countries, plus medicines sold to institutions through tenders (Cipla Global Access): ₹4,287 crore in FY26, of which South Africa ₹3,364 crore. [S16, S1]
- **Emerging markets and Europe:** Medicines sold in other emerging markets and in Europe: ₹3,576 crore in FY26, up 8%. [S16]
- **Drug ingredients (API) and others:** Active pharmaceutical ingredients, the substance in a medicine that does the work, sold to other companies, and other small items: ₹749 crore in FY26. [S16]

## Who pays Cipla?

- **Customers in India (45.0% of revenue):** Distributors and retailers that sell Cipla's prescription brands, trade generics and consumer products to patients. Share is of FY26 revenue by customer location. [S1]
- **Customers in the US (24.4% of revenue):** Buyers of Cipla's generic medicines in the US: ₹6,872 crore of revenue in FY26, down from ₹7,899 crore in FY25. [S1]
- **Customers in Africa (15.2% of revenue):** Private-market buyers in South Africa and other African countries, and governments and global health programmes buying through tenders. [S1, S16]
- **Customers in the rest of the world (15.4% of revenue):** Buyers in other emerging markets and Europe, and companies buying drug ingredients. [S1]
- **Customer concentration:** No single customer gave Cipla 10% or more of its revenue in FY26 or FY25, according to its segment note. Cipla's BRSR lists its customer types as business and institutional partners, channel partners, government agencies and individual consumers. [S1, S48]

## Where the money went (FY26)

1. In FY26 Cipla's medicines brought in ₹28,163 crore of revenue, plus ₹882 crore of other income.
2. Materials and goods bought took ₹9,549 crore and employees ₹5,366 crore.
3. Other running costs took ₹7,364 crore, and depreciation and interest ₹1,265 crore.
4. A one-off labour-code charge took ₹276 crore and income tax ₹1,354 crore.
5. What was left for Cipla's shareholders was ₹3,879 crore of profit.

Sources: S1, S15, S19.

## Key numbers by year (₹ crore)

Financials: consolidated, ₹ crore. Financial year runs April to March (March year end). — = not shown on the page.

| Year | Revenue | EBITDA | EBITDA margin | Net profit | Net margin | EPS (₹ per share) | Operating cash flow | Capital spending | Free cash flow | Sources |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| FY22 | 21,763 | 4,371 | 20.1% | 2,517 | 11.6% | 31.2 | 3,326 | 701 | 2,625 | S34, S5, S4 |
| FY23 | 22,753 | 4,845 | 21.3% | 2,802 | 12.3% | 34.72 | 3,238 | 1,183 | 2,055 | S33, S4 |
| FY24 | 25,774 | 6,096 | 23.7% | 4,122 | 16.0% | 51.05 | 4,134 | 1,349 | 2,785 | S32, S3 |
| FY25 | 27,548 | 7,128 | 25.9% | 5,273 | 19.1% | 65.29 | 5,005 | 1,548 | 3,457 | S26, S2 |
| FY26 | 28,163 | 5,607 | 19.9% | 3,879 | 13.8% | 48.03 | 3,940 | 3,079 | 861 | S15, S1, S16 |

- EBITDA = profit before interest, tax and wear-and-tear of assets.
- Net profit is the share belonging to the company's owners.

## Balance sheet (as of 30 Sep 2026, ₹ crore)

On 30 Sep 2026 Cipla's cash and liquid investments were ₹7,971 crore more than its borrowings of ₹267 crore (Cityfort calculation from the Q2 FY27 results). [S6, S7, S8]

| Item | Value |
| --- | --- |
| Total debt | 267 |
| Cash and investments | 8,238 |
| Net debt (debt minus cash) | −7,971 |
| Net worth (shareholders' money) | 35,396 |
| Debt to equity (times) | 0.01 |

- Borrowings exclude lease liabilities (rent owed under leases) of ₹432 crore.
- Cash and liquid investments = cash, other bank balances and current investments. Net worth is the equity belonging to Cipla's shareholders.
- Cipla's own measure, on its own wider definition, was a net cash position of ₹9,823 crore on 30 Sep 2026.
- NPPA demand notices under litigation total ₹2,011 crore (principal ₹863 crore, interest ₹1,148 crore); Cipla has made no provision for them (see governance signals).

## Who owns Cipla? (shareholding, Q2 FY27)

| Holder | % of shares |
| --- | --- |
| Promoters | 29.21% |
| Promoter shares pledged (% of promoter shares) | 0.0% |
| Foreign institutions (FII) | 20.25% |
| Indian institutions (DII) | 34.94% |
| Public | 15.6% |

Sources: S35, S36, S37, S38, S39, S40, S41, S42, S43, S44, S45, S46.

## What could go wrong

### US FDA status of Cipla's plants

The Pithampur plant has been classed OAI by the US FDA since Aug 2023 and had a warning letter in Nov 2023. A follow-up inspection in Aug 2026 ended with 7 observations. Cipla said OAI status may delay or withhold pending US product approvals. [S51, S52, S53]

What to watch: The US FDA's classification of the Aug 2026 Pithampur inspection.

### A few US products and partners

North America sales fell 13% in FY26 after generic Revlimid billing ended and supply of lanreotide, made by partner Pharmathen, was paused and later recalled. Achin Gupta said on 27 Oct 2026 that the US$1 billion run-rate aim does not include lanreotide. [S16, S21, S78, S80, S8, S10]

What to watch: North America sales in US dollars each quarter (US$172 million in Q2 FY27).

### Price controls and competition

Cipla's FY26 annual report says "Government price controls, competitor and customer pressures collectively erode profitability", and names more competition in chronic medicines, particularly cardiometabolic (heart and blood-sugar) and anti-obesity medicines. [S1, S8]

What to watch: One India growth each quarter (+12% in Q2 FY27) and gross margin.

### NPPA overcharging claims

The NPPA alleges Cipla overcharged for price-controlled drugs; notices under litigation total ₹2,011 crore, including ₹1,148 crore of interest. Cipla has made no provision. CARE lists this liability crystallising as a factor that could lead to a lower rating. [S7, S47]

What to watch: Supreme Court hearings on Cipla's appeal, and any provision in the results.

### Margins below earlier targets

Cipla's FY26 EBITDA margin was 21.0%, against the 23.5–24.5% range management gave in May 2025. For FY27 management gave 18.5–20%; Cipla reported 18.7% in Q2 FY27. [S28, S16, S17, S8]

What to watch: Quarterly EBITDA margin in Q3 and Q4 FY27.

### Delays in US launches

Cipla said on 27 Jul 2026 it expected to launch generic Advair in Q2 FY27; on 27 Oct 2026 Achin Gupta said it "is getting launched in Q3". Cipla said on 14 Jan 2026 it expected lanreotide resupply in H1 FY27; it had not resumed by 27 Oct 2026. [S88, S10, S78]

What to watch: Generic Advair sales and any lanreotide restart in Cipla's results releases.

## What to watch

Next: Q3 FY27 results, Date not announced yet.

- **Pithampur inspection outcome:** The US FDA's classification of the Aug 2026 follow-up inspection, which ended with 7 observations; the plant has been OAI since Aug 2023.
- **US sales and launches:** North America sales were US$172 million in Q2 FY27. On 27 Oct 2026 Achin Gupta said generic Advair would launch in Q3, and management kept its US$1 billion run-rate aim for the end of FY27.
- **Margins:** Cipla reported an 18.7% EBITDA margin in Q2 FY27; management's FY27 range, given on 13 May 2026, is 18.5–20%.

## Sources

- S1: Integrated Annual Report 2025-26 (FY26). Cipla Ltd (filed with NSE). https://nsearchives.nseindia.com/annual_reports/AR_29325_CIPLA_2025_2026_A_20783341_01062026233258.pdf (published 1 Jun 2026)
- S2: Integrated Annual Report 2024-25 (FY25). Cipla Ltd (filed with NSE). https://nsearchives.nseindia.com/annual_reports/AR_26576_CIPLA_2024_2025_A_19062025210950.pdf (published 19 Jun 2025)
- S3: Annual Report 2023-24 (FY24). Cipla Ltd (filed with NSE). https://nsearchives.nseindia.com/annual_reports/AR_24682_CIPLA_2023_2024_2607202421292.pdf (published 26 Jul 2024)
- S4: Annual Report 2022-23 (FY23; NSE zip). Cipla Ltd (filed with NSE). https://nsearchives.nseindia.com/annual_reports/AR_22441_CIPLA_2022_2023_18072023233319_07192023070005.zip (published 18 Jul 2023)
- S5: Annual Report 2021-22 (FY22; NSE zip). Cipla Ltd (filed with NSE). https://nsearchives.nseindia.com/annual_reports/AR_21310_CIPLA_2021_2022_05092022114240_09052022120012.zip (published 5 Sep 2022)
- S6: Q2 FY27 consolidated results, Integrated Filing (Financials) XBRL. Cipla Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1747271_27102026091332_WEB.xml (published 27 Oct 2026)
- S7: Unaudited financial results Q2 FY27 (quarter and half year ended 30 Sep 2026). Cipla Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/CIPLA_27102026133100_Cipla_SE_20261027_FR_Signed.pdf (published 27 Oct 2026)
- S8: Press release: Q2 FY27 financial results. Cipla Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/CIPLA_27102026133323_SE_Intimation_Press_Release_20261027_Signed.pdf (published 27 Oct 2026)
- S9: Investor presentation Q2 FY27. Cipla Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/CIPLA_27102026133753_SE_Intimation_Investor_Presentation_20261027_Signed.pdf (published 27 Oct 2026)
- S10: Q2 FY27 earnings call transcript (call 27 Oct 2026). Cipla Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/CIPLA_30102026172814_SE_Intimation_Earnings_Call_Transcript_20261027_signed.pdf (published 30 Oct 2026)
- S11: Q1 FY27 consolidated results, Integrated Filing (Financials) XBRL. Cipla Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1700278_23072026063436_WEB.xml (published 23 Jul 2026)
- S14: Q1 FY27 earnings call transcript (call 23 Jul 2026). Cipla Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/CIPLA_27072026171448_SEIntimationEarningscalltranscriptQ1FY27.pdf (published 27 Jul 2026)
- S15: Q4 FY26 / FY26 consolidated results, Integrated Filing (Financials) XBRL. Cipla Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1666727_13052026085507_WEB.xml (published 13 May 2026)
- S16: Press release: Q4 FY26 and FY26 results. Cipla Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/CIPLA_13052026125750_SignedPressrelease13052026Signed.pdf (published 13 May 2026)
- S17: Q4 FY26 earnings call transcript (call 13 May 2026). Cipla Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/CIPLA_15052026182859_EarningscalltranscriptMay26signedrc.pdf (published 15 May 2026)
- S18: Q3 FY26 consolidated results, Integrated Filing (Financials) XBRL. Cipla Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1609444_23012026061822_WEB.xml (published 23 Jan 2026)
- S19: Unaudited financial results Q3 FY26 (quarter ended 31 Dec 2025; scanned). Cipla Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/CIPLA_23012026132656_SignedFinancialResults_31122025_Signed.pdf (published 23 Jan 2026)
- S21: Q3 FY26 earnings call transcript (call 23 Jan 2026). Cipla Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/CIPLA_27012026194052_Cipla-Earnings-Jan23-2026_Signed.pdf (published 27 Jan 2026)
- S22: Q2 FY26 consolidated results, Integrated Filing (Financials) XBRL. Cipla Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1562232_30102025100011_WEB.xml (published 30 Oct 2025)
- S23: Press release: Q2 FY26 results. Cipla Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/CIPLA_30102025135340_CiplaQ2FY26PressReleasesigned.pdf (published 30 Oct 2025)
- S24: Q1 FY26 consolidated results, Integrated Filing (Financials) XBRL. Cipla Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1493477_25072025043236_WEB.xml (published 25 Jul 2025)
- S26: Q4 FY25 / FY25 consolidated results, Integrated Filing (Financials) XBRL. Cipla Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1437887_13052025092912_WEB.xml (published 13 May 2025)
- S27: Press release: Q4 FY25 and FY25 results. Cipla Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/CIPLA_13052025142118_Signed_Pressrelease13052025_signed.pdf (published 13 May 2025)
- S28: Q4 FY25 earnings call transcript (call 13 May 2025). Cipla Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/CIPLA_16052025164608_EarningscalltranscriptMay25_signed.pdf (published 16 May 2025)
- S29: Q3 FY25 consolidated results XBRL. Cipla Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/INDAS_117946_1364025_29012025113424.xml (published 29 Jan 2025)
- S31: Press release: Q4 FY24 and FY24 results. Cipla Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/CIPLA_10052024144218_CiplaPressRelease10042024signed.pdf (published 10 May 2024)
- S32: Q4 FY24 / FY24 consolidated results XBRL. Cipla Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/INDAS_105691_1120842_11052024101949.xml (published 11 May 2024)
- S33: Q4 FY23 / FY23 consolidated results XBRL. Cipla Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/INDAS_91654_841981_12052023100257.xml (published 12 May 2023)
- S34: Q4 FY22 / FY22 consolidated results XBRL. Cipla Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/INDAS_84235_652971_11052022030052_WEB.xml (published 11 May 2022)
- S35: Shareholding pattern as of 31 Dec 2023 (NSE XBRL). NSE (company filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_185149_1030806_19012024090106_WEB.xml (published 19 Jan 2024)
- S36: Shareholding pattern as of 31 Mar 2024 (NSE XBRL). NSE (company filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_188024_1102766_19042024084143_WEB.xml (published 19 Apr 2024)
- S37: Shareholding pattern as of 30 Jun 2024 (NSE XBRL). NSE (company filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_190671_1197737_20072024050543_WEB.xml (published 20 Jul 2024)
- S38: Shareholding pattern as of 30 Sep 2024 (NSE XBRL). NSE (company filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_193566_1283925_21102024074044_WEB.xml (published 21 Oct 2024)
- S39: Shareholding pattern as of 31 Dec 2024 (NSE XBRL). NSE (company filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_195757_1353977_20012025085509_WEB.xml (published 20 Jan 2025)
- S40: Shareholding pattern as of 31 Mar 2025 (NSE XBRL). NSE (company filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_198794_1421427_21042025050649_WEB.xml (published 21 Apr 2025)
- S41: Shareholding pattern as of 30 Jun 2025 (re-filed 21 Oct 2025) (NSE XBRL). NSE (company filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1555034_21102025074617_WEB.xml (published 21 Oct 2025)
- S42: Shareholding pattern as of 30 Sep 2025 (NSE XBRL). NSE (company filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1555036_21102025075059_WEB.xml (published 21 Oct 2025)
- S43: Shareholding pattern as of 31 Dec 2025 (NSE XBRL). NSE (company filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1607774_21012026090606_WEB.xml (published 21 Jan 2026)
- S44: Shareholding pattern as of 31 Mar 2026 (revised filing 11 Aug 2026; original 21 Apr 2026) (NSE XBRL). NSE (company filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1712107_11082026072853_WEB.xml (published 11 Aug 2026)
- S45: Shareholding pattern as of 30 Jun 2026 (NSE XBRL). NSE (company filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1698044_21072026022401_WEB.xml (published 21 Jul 2026)
- S46: Shareholding pattern as of 30 Sep 2026 (NSE XBRL). NSE (company filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1743615_21102026092948_WEB.xml (published 21 Oct 2026)
- S47: CARE Ratings press release: Cipla Limited, bank facilities reaffirmed CARE AAA; Stable / CARE A1+. CARE Ratings Limited. https://www.careratings.com/upload/CompanyFiles/PR/202508120858_Cipla_Limited.pdf (published 26 Aug 2025)
- S48: Business Responsibility and Sustainability Report FY26. Cipla Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/CIPLA_01062026233621_Cipla_BRSR_FY26_signed.pdf (published 1 Jun 2026)
- S49: NSE capital market bhavcopy, 11 Nov 2026 (CIPLA EQ close). National Stock Exchange of India. https://nsearchives.nseindia.com/content/cm/BhavCopy_NSE_CM_0_0_0_20261111_F_0000.csv.zip (published 11 Nov 2026)
- S51: USFDA classifies Pithampur inspection as Official Action Indicated (OAI). Cipla Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/CIPLA_05082023201729_SEDisclosure.pdf (published 5 Aug 2023)
- S52: USFDA Warning Letter dated 17 Nov 2023 for Pithampur. Cipla Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/CIPLA_18112023215134_USFDAWarningLetterPithampur.pdf (published 18 Nov 2023)
- S53: USFDA follow-up cGMP inspection at Pithampur, 17-25 Aug 2026: 7 observations in Form 483. Cipla Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/CIPLA_25082026161031_USFDA_inspection_-_Pithampur_25082026_Signed.pdf (published 25 Aug 2026)
- S56: USFDA classifies Goa inspection (Jun 2024) as VAI. Cipla Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/CIPLA_30102024213353_USFDA_letter_signed.pdf (published 30 Oct 2024)
- S58: USFDA classifies Patalganga inspection as VAI. Cipla Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/CIPLA_25062024111116_SEIntimationUSFDAPG.pdf (published 25 Jun 2024)
- S60: USFDA classifies Kurkumbh inspection as VAI. Cipla Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/CIPLA_13072024114403_SEintimationUSFDAKKB13072024.pdf (published 13 Jul 2024)
- S62: USFDA classifies Virgonagar inspection as VAI. Cipla Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/CIPLA_08022025104448_StockExchangeIntimationUSFDAVAIVirgonagar.pdf (published 8 Feb 2025)
- S68: USFDA classifies Bommasandra inspection as VAI. Cipla Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/CIPLA_05082025090344_USFDA05082025.pdf (published 5 Aug 2025)
- S72: USFDA classifies Verna (Goa) Apr 2026 inspection as VAI. Cipla Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/CIPLA_11062026140431_USFDAoutcomeofinspectionGoa11062026_Signed.pdf (published 11 Jun 2026)
- S77: Clarification: USFDA Form 483 at partner Pharmathen (lanreotide supplier). Cipla Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/CIPLA_07012026181456_FinalSEIntimation_USFDA_07012026_Signed.pdf (published 7 Jan 2026)
- S78: Update on lanreotide supply after USFDA observations at Pharmathen. Cipla Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/CIPLA_14012026231015_Covering_SE_intimation_Lanreotide.pdf (published 14 Jan 2026)
- S79: USFDA classifies Pharmathen (Rodopi, Greece) inspection as OAI. Cipla Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/CIPLA_21022026174937_SignedUSFDA-inspection-Pharmathen21022026Signed.pdf (published 21 Feb 2026)
- S80: Cipla USA to recall unexpired lanreotide batches. Cipla Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/CIPLA_09032026225014_SignedUSFDA-inspection-Pharmathen09032026Signed_1.pdf (published 9 Mar 2026)
- S81: Umang Vohra resigns as director w.e.f. 1 Apr 2026 on completing his term as MD & Global CEO. Cipla Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/CIPLA_30032026182231_Signed_SMP_intimation_30_March_2026.pdf (published 30 Mar 2026)
- S82: Board recommends B S R & Co. LLP as statutory auditor from the 90th AGM. Cipla Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/CIPLA_13052025140043_SignedIntimationforAuditorsappointmentSigned.pdf (published 13 May 2025)
- S83: 90th AGM approves B S R & Co. LLP; Walker Chandiok & Co LLP completes second term. Cipla Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/CIPLA_25062026215937_IntimationforAuditorsappointment_Finalsigned.pdf (published 25 Jun 2026)
- S84: Clarification: promoter group members sold 2.53% of shares on 15 May 2024. Cipla Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/CIPLA_15052024093337_SEIntimationSigned.pdf (published 15 May 2024)
- S85: Launch of Yurpeak (tirzepatide) in India under distribution agreement with Eli Lilly. Cipla Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/CIPLA_10122025160345_Press_Release_Cipla_launches_Yurpeak_signed.pdf (published 10 Dec 2025)
- S86: Exclusive 5-year supply and marketing agreement for four Pfizer brands in India. Cipla Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/CIPLA_19122025112751_SE_Pfizer_deal_19122025_Final_Signed.pdf (published 19 Dec 2025)
- S87: USFDA approval for first AB-rated generic of Ventolin HFA (albuterol). Cipla Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/CIPLA_23042026094557_gVentolonSEIntimationv2Signed.pdf (published 23 Apr 2026)
- S88: USFDA approval for generic Advair Diskus. Cipla Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/CIPLA_27072026225403_FinalGAdvairLaunchSEIntimationSigned.pdf (published 27 Jul 2026)
- S90: 60:40 biologics joint venture agreement with Kemwell Biopharma. Cipla Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/CIPLA_02032026195825_SEkemwell2026v2signed.pdf (published 2 Mar 2026)
- S91: Board: up to US$100 mn into Cipla (EU) for InvaGen; P R Ramesh Vice-Chairman. Cipla Ltd (filing to NSE/BSE). https://nsearchives.nseindia.com/corporate/CIPLA_19032026173251_Signed_OutcomeBoardmeeting19thMarch2026.pdf (published 19 Mar 2026)
- S92: Sun Pharmaceutical Industries: investor presentation, September 2026 (India formulation market share chart, AIOCD AWACS MAT Jun 2026). Sun Pharmaceutical Industries Ltd (company IR site). https://sunpharma.com/wp-content/uploads/2026/09/SPIL-IR-Presentation-Sept-2026-INR-1.pdf (published 22 Sep 2026)
